The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | GvHD prophylaxis: PTCY vs ATG in AML with allo-HSCT
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the retrospective analysis from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). The aim of this study was to compare graft-versus-host disease (GvHD) prophylaxis containing either post-transplant cyclophosphamide (PTCY) or anti-thymocyte globulin (ATG) in patients diagnosed with acute myeloid leukemia (AML) and undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-identical matched sibling donor (MSD). Prof. Mohty reveals PTCY is a valid option for GvHD prophylaxis, except for chronic GVHD for which a protective effect of ATG is confirmed. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
